CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Abroad (travel likely)RecruitingPHASE1

Conditions

Systemic Lupus Erythematosus · Systemic Sclerosis (SSc) · Inflammatory Myopathy · ANCA-Associated Vasculitis (AAV) · Connective Tissue Disease-Associated Thrombocytopenia · SLE-ITP

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Tianjin, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Hefei, China

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS)

Abroad (travel likely)RecruitingPHASE1

Xuzhou, China · Xuzhou, China

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome (SS) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Beijing, China